tldrdailynews.com logo

Hormone combo around surgery may redefine care for high-risk prostate cancer

1 min read
Source: statnews.com
Hormone combo around surgery may redefine care for high-risk prostate cancer
Photo: statnews.com
TL;DR Summary

A phase 3 PROTEUS trial shows that administering two hormone therapies both before and after prostate cancer surgery improves outcomes versus a single hormone therapy in high-risk, early-stage patients, a result that some doctors see as paving the way for a potential new standard of care.

Topics:business#cancer-research#health#hormone-therapy#prostate-cancer#proteus-trial#surgery
Share this article
  1. For prostate cancer patients set on surgery, new hormone regimen may improve outcomes, study finds  statnews.com
  2. J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study  Reuters
  3. ASCO: J&J breaks the prostate cancer treatment mold with fresh Erleada ph. 3 win  Fierce Pharma
  4. PROTEUS: Apalutamide plus ADT before and after RP cuts metastasis risk  Urology Times
  5. ASCO26: Big win for Erleada in perioperative prostate cancer  pharmaphorum

Reading Insights

Total Reads

0

Unique Readers

11

Time Saved

2 min

vs 3 min read

Condensed

90%

479 → 46 words

Want the full story? Read the original article

Read on statnews.com